Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penwest Pharmaceuticals Co.

Division of Endo International PLC
www.penwest.com

Latest From Penwest Pharmaceuticals Co.

Owning the Disease: A New Business Model For Medical Technology Companies

The convergence of expanded access, lower reimbursement rates, higher velocity of innovation, diminished pools of venture capital, the advent of personalized care and a growing demand for improved patient outcomes has created ripples that already are altering the economics and operating dynamics of health care. To survive the coming storm, biomedical companies must build new models of innovation that are anchored in consumer-centric disease solutions rather than the traditional R&D department approaches.

Medical Device Innovation

Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q2 2011

During the second quarter of 2011, 57 medical device companies brought in a total of $1.7 billion in financings. The M&A activity reached $28.8 billion, unusually high due to Johnson & Johnson's $21.7 billion takeover of orthopedic device maker Synthes. VC funding represented $76 million or 43% of the second quarter's in vitro diagnostics/research financing aggregate of $177 million. A hefty $4.1 billion was spent on 11 in vitro diagnostic/research M&A transactions, the largest being Thermo Fisher's $3.5 billion buy of Swedish genetics testing firm Phadia AB.
Medical Device

How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees

Biotech executives make strategic decisions based on incentives that aren't necessarily aligned to benefit either the company's investors or employees. Three modifications to business as usual would help solve the problem and lead to improvements in the productivity of people and capital in the sector.
BioPharmaceutical Europe

Endo diversifies with $2.9 billion devices acquisition

US speciality healthcare firm Endo Pharmaceuticals has agreed to acquire pelvic health device developer American Medical Systems (AMS) for $2.9bn. The deal is part of Endo's plan to move from being a product-driven company to a healthcare solutions provider, and will also increase its foothold in the medical device industry.

Gynecology & Urology Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endo International PLC
  • Senior Management
  • Jennifer L Good, Pres. & CEO
    Anand R Baichwal, PhD, SVP, Licensing & Bus. Dev.
    Thomas R Sciascia, MD, SVP, CMO
  • Contact Info
  • Penwest Pharmaceuticals Co.
    Phone: (845) 878-8400
    2981 Rte. 22
    Patterson, NY 12563
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register